JP2011500690A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500690A5
JP2011500690A5 JP2010530005A JP2010530005A JP2011500690A5 JP 2011500690 A5 JP2011500690 A5 JP 2011500690A5 JP 2010530005 A JP2010530005 A JP 2010530005A JP 2010530005 A JP2010530005 A JP 2010530005A JP 2011500690 A5 JP2011500690 A5 JP 2011500690A5
Authority
JP
Japan
Prior art keywords
composition
subject
blood glucose
glucose level
fasting blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500690A (ja
JP5558358B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/075433 external-priority patent/WO2009051908A1/en
Publication of JP2011500690A publication Critical patent/JP2011500690A/ja
Publication of JP2011500690A5 publication Critical patent/JP2011500690A5/ja
Application granted granted Critical
Publication of JP5558358B2 publication Critical patent/JP5558358B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530005A 2007-10-16 2008-09-05 メタボリック症候群用のtrans−クロミフェン Expired - Fee Related JP5558358B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98033407P 2007-10-16 2007-10-16
US60/980,334 2007-10-16
PCT/US2008/075433 WO2009051908A1 (en) 2007-10-16 2008-09-05 Trans-clomiphene for metabolic syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014114963A Division JP5856652B2 (ja) 2007-10-16 2014-06-03 メタボリック症候群用のtrans−クロミフェン

Publications (3)

Publication Number Publication Date
JP2011500690A JP2011500690A (ja) 2011-01-06
JP2011500690A5 true JP2011500690A5 (OSRAM) 2011-10-13
JP5558358B2 JP5558358B2 (ja) 2014-07-23

Family

ID=40023452

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010530005A Expired - Fee Related JP5558358B2 (ja) 2007-10-16 2008-09-05 メタボリック症候群用のtrans−クロミフェン
JP2014114963A Expired - Fee Related JP5856652B2 (ja) 2007-10-16 2014-06-03 メタボリック症候群用のtrans−クロミフェン
JP2015241230A Pending JP2016040328A (ja) 2007-10-16 2015-12-10 メタボリック症候群用のtrans−クロミフェン
JP2017123973A Pending JP2017160273A (ja) 2007-10-16 2017-06-26 メタボリック症候群用のtrans−クロミフェン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014114963A Expired - Fee Related JP5856652B2 (ja) 2007-10-16 2014-06-03 メタボリック症候群用のtrans−クロミフェン
JP2015241230A Pending JP2016040328A (ja) 2007-10-16 2015-12-10 メタボリック症候群用のtrans−クロミフェン
JP2017123973A Pending JP2017160273A (ja) 2007-10-16 2017-06-26 メタボリック症候群用のtrans−クロミフェン

Country Status (24)

Country Link
US (2) US8372887B2 (OSRAM)
EP (2) EP2826475B1 (OSRAM)
JP (4) JP5558358B2 (OSRAM)
KR (1) KR101493472B1 (OSRAM)
CN (2) CN101896174B (OSRAM)
AR (1) AR069541A1 (OSRAM)
BR (1) BRPI0818637A2 (OSRAM)
CA (3) CA2702710C (OSRAM)
CL (1) CL2008002999A1 (OSRAM)
CO (1) CO6270215A2 (OSRAM)
CR (1) CR11418A (OSRAM)
EA (2) EA022760B1 (OSRAM)
EC (1) ECSP10010106A (OSRAM)
ES (1) ES2718912T3 (OSRAM)
IL (1) IL205053A (OSRAM)
ME (1) ME00996B (OSRAM)
MX (1) MX2010004195A (OSRAM)
MY (1) MY150082A (OSRAM)
NI (1) NI201000053A (OSRAM)
NZ (2) NZ585389A (OSRAM)
SG (1) SG185311A1 (OSRAM)
TW (1) TW200918093A (OSRAM)
UA (1) UA96076C2 (OSRAM)
WO (1) WO2009051908A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2453337C (en) 2001-07-09 2012-08-28 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
NZ560551A (en) 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
ES2718912T3 (es) 2007-10-16 2019-07-05 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de la diabetes en hombres hipogonadales
TW201500041A (zh) * 2008-11-07 2015-01-01 Repros Therapeutics Inc 用於代謝症候群與第2型糖尿病的反式氯米芬
EP2616078B1 (en) * 2010-09-16 2019-12-25 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
ES2681023T3 (es) * 2012-02-29 2018-09-11 Repros Therapeutics Inc. Terapia de combinación para tratar el déficit de andrógenos
AU2013306393A1 (en) 2012-08-21 2015-02-19 Repros Therapeutics Inc. Trans-clomiphene formulations and uses thereof
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
US20160051495A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America Oral Transmucosal Compositions including C-SERMs for Low Testosterone Levels in Men
US20160051565A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America (Pcca) Transdermal Pharmaceutical Compositions Including Testosterone and an Aromatase Inhibitor
WO2016089904A1 (en) * 2014-12-02 2016-06-09 Repros Therapeutics Inc. Trans-clomiphene and its analogues as agents for treating or preventing filovirus diseases
EP3167869B1 (en) 2015-11-16 2025-02-12 Capsugel Belgium NV Tamperproof oral dosage form
EP3167870B1 (en) 2015-11-16 2024-01-03 Capsugel Belgium NV Tamperproof oral dosage form
RU2611936C1 (ru) * 2016-02-16 2017-03-01 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга" Способ моделирования гипогонадизма, вызванного метаболическими нарушениями
EP3419611A4 (en) * 2016-02-25 2019-10-16 Aspen Park Pharmaceuticals Inc. ORAL PHARMACEUTICAL FORM OF CLOMIPHIC ISOMERS AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF SECONDARY HYPOGONADISM
US12059403B2 (en) * 2016-08-04 2024-08-13 University Of Iowa Research Foundation Use of SWELL1 inhibitors and modulators to treat type 2 diabetes and obesity

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
BE637389A (OSRAM) 1962-09-13
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
DE2658307C2 (de) 1976-12-22 1979-03-15 Klinge Pharma Gmbh & Co, 8000 Muenchen Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0002097B1 (en) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
IE58417B1 (en) 1984-04-27 1993-09-22 Ici Plc Chemical derivatives
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US5352795A (en) 1986-03-07 1994-10-04 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
EP0260066B1 (en) 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
US4820736A (en) 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8714013D0 (en) 1987-06-16 1987-07-22 Ici Plc (substituted-aralkyl)heterocyclic compounds
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB8926171D0 (en) 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
KR950701317A (ko) 1992-05-08 1995-03-23 오오쓰까 아끼히꼬 인돌 유도체(Indole Derivative)
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
GB9326332D0 (en) 1993-12-23 1994-02-23 Karo Bio Indole derivatives
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JP2964871B2 (ja) 1994-04-20 1999-10-18 ノーリツ鋼機株式会社 ネガマスク装置
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
JPH10501814A (ja) 1994-06-17 1998-02-17 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ 生物的作用物質用のイン・シツゲル形成デリバリービヒクルおよびその使用方法
DE4426625A1 (de) 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
AU6824996A (en) 1995-08-17 1997-03-12 Dyer, Alison Margaret Controlled release products
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
PL327831A1 (en) 1996-01-11 1999-01-04 Novo Nordisk As Application of 3,4-diphenylchromanes in production of a pharmaceutic agent for treating or preventing menopause symptoms
HUP9901633A3 (en) 1996-01-11 2000-02-28 Novo Nordisk As Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5985910A (en) 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2565163T3 (es) 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
IL132120A0 (en) 1997-04-03 2001-03-19 Guilford Pharm Inc Biodegradable terephthalate polyester-poly (phosphate) polymers compositions articles and methods for making and using the same
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
ZA982818B (en) 1997-04-09 1999-10-04 Lilly Co Eli Prevention of breast cancer using selective estrogen receptor modulators.
ZA982819B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
JP2001513501A (ja) 1997-08-07 2001-09-04 イーライ・リリー・アンド・カンパニー エストロゲン阻害活性を有する1−[4−(置換アルコキシ)ベンジル]ナフタレン化合物
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6548491B2 (en) 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6069153A (en) 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
EP1100330A4 (en) 1998-07-30 2004-04-14 Stoller Ets TREATMENT OF PLANTS WITH SALICYLIC ACID AND ORGANIC AMINES
US6262098B1 (en) 1998-08-07 2001-07-17 Chiron Corporation Estrogen receptor modulators
DE69935335T2 (de) 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CO5180583A1 (es) 1999-06-11 2002-07-30 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales a las mujeres
AU6132700A (en) 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
US6340774B1 (en) 2000-01-31 2002-01-22 The Board Of Trustees Of The Leland Stanford Junior University Non-steroidal estrogen-receptor antagonists
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2001091744A1 (en) 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US7041839B2 (en) 2000-06-22 2006-05-09 Northeastern University Steroidal antiestrogens and antiandrogens and uses thereof
CN100448487C (zh) * 2000-08-11 2009-01-07 惠氏公司 治疗雌激素受体阳性癌的方法
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US6599921B2 (en) 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
CA2453337C (en) * 2001-07-09 2012-08-28 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
JP2005528320A (ja) 2001-08-11 2005-09-22 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 選択的なエストロゲン受容体モジュレーター
EP1418900A4 (en) 2001-08-13 2006-01-25 Merck & Co Inc SELECTIVE ESTROGEN RECEPTOR MODULATORS
EP1429779A2 (en) 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
SI1501819T1 (sl) 2002-04-24 2011-01-31 Merck Sharp & Dohme Modulatorji estrogen receptorjev
MX2007000050A (es) 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
KR20070100811A (ko) * 2005-02-04 2007-10-11 레프로스 쎄라피우틱스 아이엔씨. 남성불임의 치료를 위한 트랜스―클로미펜을 이용한 물질과치료방법
EP1853298A2 (en) * 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
NZ560551A (en) * 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
CN101309702A (zh) 2005-08-05 2008-11-19 雷普罗斯治疗公司 使用克罗米酚治疗女性不育症的方法及其组合物
EP1829534A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
ES2718912T3 (es) 2007-10-16 2019-07-05 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de la diabetes en hombres hipogonadales

Similar Documents

Publication Publication Date Title
JP2011500690A5 (OSRAM)
USD631670S1 (en) Insulation material
JP2012512907A5 (OSRAM)
JP2009535462A5 (OSRAM)
IL259851A (en) Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders
JP2011518833A5 (OSRAM)
JP2012184234A5 (OSRAM)
HRP20171175T1 (hr) Novi triciklički spojevi
HK1203514A1 (en) D-amino acid compounds for liver disease
JP2007302689A5 (OSRAM)
WO2007104641A3 (de) Superabsorber mit verbesserter geruchsinhibierung
ATE524570T1 (de) Metallfolie
JP2011527299A5 (OSRAM)
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
JP2009537554A5 (OSRAM)
JP2012512863A5 (OSRAM)
JP2014503593A5 (OSRAM)
IL200034A0 (en) 18f fluoro-benzoyl labelled biological active compounds as diagnostic imaging agents as wells as benzotriazol-1-yloxy-benzoyl, 2,5-dioxo-(pyrrolidin-1-yloxy) benzoyl and trimethylammonio-benzoyl precursers
WO2011031073A3 (ko) 신규한 테트라아자 거대고리 화합물, 제조방법 및 그 용도
WO2011089234A8 (en) Aqueous solution comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
JP2008513510A5 (OSRAM)
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
WO2012058292A3 (en) Parathyroid hormone variants and assays related to disease
IL208751A0 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
JP2008517059A5 (OSRAM)